[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583390":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":43,"collaborators":45,"id":54,"slug":10,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":66,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":10,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University of Utah","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"LMS Probands",null,"LMS Probands are the first person in a family to be known to have a germline predisposition gene mutation in LMS. A cohort of patients with a histologically confirmed leiomyosarcoma diagnosis will be prospectively recruited from two SPORE prospective biomarker studies.",{"label":13,"type":10,"description":14,"interventionNames":10},"Relative of LMS Probands","Relatives to LMS probands will be enrolled in this cohort. Approximately 4 family members per proband will be recruited.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Gregg Wood","CONTACT","8016464215","gregg.wood@hci.utah.edu",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Huntsman Cancer Institute at the University of Utah","RECRUITING","Salt Lake City","Utah","84112","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-111.89105,40.76078,{"lat":34,"lon":33},[37,41],{"name":38,"role":18,"phone":39,"phoneExt":10,"email":40},"Wendy K Kohlmann, MS","801-587-5556","wendy.kohlmann@hci.utah.edu",{"name":38,"role":42,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[46,49,52],{"name":47,"class":48},"National Cancer Institute (NCI)","NIH",{"name":50,"class":51},"University of New South Wales","UNKNOWN",{"name":53,"class":6},"University of Michigan","100583390",false,"NCT06875700","Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients","Beliefs, Attitudes, and Response to Genetic Testing in Sarcoma Patients","Inclusion LMS Proband\n\n* Actionable germline PV detected in the research context\n* Living\n* No prior germline testing for this PV\n* Able to speak and read English\n* Mentally competent\n* Age 18 or older\n\nRelative of LMS Proband\n\n* 25-50% chance for having inherited the PV\n* No prior germline testing for this PV\n* Able to speak and read English\n* Mentally competent\n* Age 18 or older\n\nExclusion (both cohorts)\n\n* \\\u003C18 years\n* Unable to read or write",true,"ALL","18 Years",{"count":64,"type":65},300,"ESTIMATED","3 Months","OBSERVATIONAL","Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients. This study is assessing the beliefs about the heritability of leiomyosarcoma and other cancer risks, and attitudes towards germline testing among leiomyosarcoma patients.",[70],"Leiomyosarcoma","2025-06-11",{"date":73,"type":74},"2025-06-13","ACTUAL",{"date":76,"type":74},"2024-07-09",{"date":78,"type":65},"2027-08",{"name":5,"class":6},1]